A novel diagnostic method for malignant IPMN based on the results of proteomics

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08423
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Okayama University
• Principal Investigator: Tsutsumi Koichiro 岡山大学, 大学病院, 助教 (40610910)
• Co-Investigator(Kenkyū-buntansha): 白羽 英則 岡山大学, 大学病院, 講師 (40379748) ; 加藤 博也 岡山大学, 大学病院, 准教授 (60619039)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: IPMN / プロテオミクス / 膵液診断マーカー / 良悪性診断

Outline of Final Research Achievements

Proteomics revealed that the Protein A was the most frequently detected protein in high grade dysplasia (HGD), and was not detected in low grade dysplasia (LGD), using 9 FFPE tissues of resected branched-type IPMN. As the verification, the immunohistochemistry confirmed that the expression scores of Protein A were significantly higher in HGD lesions than in LGD lesions, in total 40 tissues. Furthermore, the expression levels in pancreatic juice (PJ) were higher in the lesions with IPMC than in them with IPMA. This is the first study to expect the Protein A may be a useful biomarker for distinguishing malignant IPMN with benign IPMN, using preoperative collected PJs.

Free Research Field

消化器内科

Academic Significance and Societal Importance of the Research Achievements

本研究では、術前良悪性診断が困難な分枝型IPMNのプロテオーム解析により、悪性マーカーとなりうるProtein Aを同定した。さらに臨床応用を目指して、術前膵液中のProtein Aの定量化により、術前の悪性化予測が比較的高精度に可能なことが示唆された。以上から、術前膵液採取によるProtein A測定により、IPMNの良悪性鑑別診断能向上が得られることが明らかとなり、適切な手術のタイミングや不要な手術を回避するといった、適格な手術適応判断の一助として有望な診断法となりうる成果が得られた。